Shenling Baizhu San ameliorates non-alcoholic fatty liver disease in mice by modulating gut microbiota and metabolites

Purpose: The prevalence of non-alcoholic fatty liver disease (NAFLD) and its related mortality is increasing at an unprecedented rate. Traditional Chinese medicine (TCM) has been shown to offer potential for early prevention and treatment of NAFLD. The new mechanism of “Shenling Baizhu San” (SLBZS)...

书目详细资料
发表在:	Frontiers in Pharmacology
Main Authors:	Dongliang Chen, Yuanfei Wang, Jianmei Yang, Wanyi Ou, Guiru Lin, Ze Zeng, Xiaomin Lu, Zumin Chen, Lili Zou, Yaling Tian, Aiping Wu, Shelley E. Keating, Qinhe Yang, Chenli Lin, Yinji Liang
格式:	文件
语言:	英语
出版:	Frontiers Media S.A. 2024-04-01
主题:	non-alcoholic fatty liver disease gut microbiota metabolites traditional Chinese medicine metabolic-associated steatotic liver disease
在线阅读:	https://www.frontiersin.org/articles/10.3389/fphar.2024.1343755/full

相似书籍

Correlation of intestinal bacteria, fungi and dietary nutrient intake in NAFLD patients with spleen deficiency syndrome
由: Guiru Lin, et al.
出版: (2025-08-01)

Liver Stiffness, Not Steatosis, Predicts Mortality in MASLD Patients: An NHANES Analysis
由: Yuting Huang, et al.
出版: (2024-12-01)

Mitochondrial Dysfunction-Associated Mechanisms in the Development of Chronic Liver Diseases
由: Madan Kumar Arumugam, et al.
出版: (2023-10-01)

Treatment of HCV infection in patients with steatotic liver disease
由: Robert Flisiak, et al.
出版: (2024-07-01)

Evaluation of Liver Fibrosis through Noninvasive Tests in Steatotic Liver Disease
由: Yuri Cho
出版: (2024-11-01)

Prognosis of biopsy-confirmed metabolic dysfunction-associated steatotic liver disease: A sub-analysis of the CLIONE study
由: Michihiro Iwaki, et al.
出版: (2024-04-01)

Corrigendum: Pyroptosis and gasdermins—Emerging insights and therapeutic opportunities in metabolic dysfunction-associated steatohepatitis
由: Christian Stoess, et al.
出版: (2024-10-01)

Pyroptosis and gasdermins—Emerging insights and therapeutic opportunities in metabolic dysfunction-associated steatohepatitis
由: Christian Stoess, et al.
出版: (2023-08-01)

Study on the regulation of brain–gut peptide by Shenling Baizhu San in functional diarrhea rats
由: Yuan Li, et al.
出版: (2018-07-01)

Impact of steatotic liver disease subtypes, sarcopenia, and fibrosis on all-cause and cause-specific mortality: a 15.7-year cohort study
由: Yebei Liang, et al.
出版: (2025-02-01)

Correspondence to letter to the editor 2 on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study”
由: Seogsong Jeong, et al.
出版: (2025-04-01)

Effects of dietary live microbes intake on a newly proposed classification system for steatotic liver disease
由: Zhikun Dai, et al.
出版: (2025-02-01)

Prevalence of steatotic liver disease and associated fibrosis in the general population: An epidemiological survey: Letter to the editor on “Epidemiology of metabolic dysfunction-associated steatotic liver disease”
由: Lin Guan, et al.
出版: (2025-04-01)

Steatotic Liver Disease: New Nomenclature and Its Localization in the Russian Federation
由: K. L. Raikhelson, et al.
出版: (2024-05-01)

Sex disparities in alcohol-associated liver disease and subtype differences in alcohol-attributable cancers in the United States
由: Pojsakorn Danpanichkul, et al.
出版: (2025-07-01)

Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity
由: Gi-Ae Kim, et al.
出版: (2023-10-01)

Role of waist circumference, body mass index and high-sensitivity C-reactive protein in pediatric steatotic liver disease: A cross-sectional study
由: Qiaoling Wu, et al.
出版: (2025-01-01)

Metabolic associated steatotic liver disease misses fewer high-risk patients than metabolic associated fatty liver disease
由: Yu-Ming Cheng, et al.
出版: (2024-12-01)

Risk of Hepatocellular Carcinoma by Steatotic Liver Disease and Its Newly Proposed Subclassification
由: Byeong Geun Song, et al.
出版: (2024-03-01)

Serum metabolites characterize hepatic phenotypes and reveal shared pathways: results from population-based imaging
由: Juliane Maushagen, et al.
出版: (2025-07-01)

The Impact of Metabolic Health and Obesity on Liver Transplant Candidates and Recipients
由: Alexander S. Vogel, et al.
出版: (2024-05-01)

TM6SF2 and PNPLA3: A potential dynamic duo?: Editorial on “TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD”
由: Andrea Caddeo, et al.
出版: (2025-01-01)

Characteristics and long-term mortality of individuals with MASLD, MetALD, and ALD, and the utility of SAFE score
由: Pimsiri Sripongpun, et al.
出版: (2024-10-01)

Common Denominator of MASLD and Some Non-Communicable Diseases
由: Katarzyna Ferenc, et al.
出版: (2024-06-01)

Prevention of polycystic ovary syndrome and postmenopausal osteoporosis by inhibiting apoptosis with Shenling Baizhu powder compound
由: Jing Liang, et al.
出版: (2022-10-01)

Sequential Diagnostic Approach Using FIB-4 and ELF for Predicting Advanced Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease
由: Yeo-Wool Kang, et al.
出版: (2024-11-01)

Towards unification of liver stiffness measurement cutoffs: Editorial on “Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis”
由: Yangyue Zhang, et al.
出版: (2025-01-01)

Differential prevalence and prognostic value of metabolic syndrome components among patients with MASLD
由: Jesse Pustjens, et al.
出版: (2024-12-01)

Network pharmacology and gut microbiota insights: unraveling Shenling Baizhu powder’s role in psoriasis treatment
由: Bin Tang, et al.
出版: (2024-02-01)

The clinician's view on the advantages and contradictions of the new nomenclature of steatotic liver disease: A review
由: Chavdar S. Pavlov, et al.
出版: (2024-05-01)

Inter- and Intraobserver variability of attenuation coefficient measurement in innovative ultrasound diagnosis of metabolic dysfunction-associated steatotic liver disease: a cross-sectional study
由: Maksym Zhaivoronok, et al.
出版: (2025-03-01)

METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE: UPDATE
由: Maria Gabriela Fernandes DEZAN, et al.
出版: (2025-09-01)

MASLD-related HCC: Multicenter study comparing patients with and without cirrhosis
由: Carole Vitellius, et al.
出版: (2024-10-01)

Phosphorylation: new star of pathogenesis and treatment in steatotic liver disease
由: Tiansu Lv, et al.
出版: (2024-02-01)

Liver fibrosis increases the risk of subclinical atherosclerosis in patients with MASLD: a cross-sectional and longitudinal study
由: Haoyu Zhang, et al.
出版: (2025-07-01)

Validation of the American Association for the Study of Liver Disease/European Association for the Study of the Liver Multistep Screening Strategies for Metabolic Dysfunction-associated Steatotic Liver disease
由: Clémence Marie Canivet, et al.
出版: (2025-01-01)

From Dysbiosis to Hepatic Inflammation: A Narrative Review on the Diet-Microbiota-Liver Axis in Steatotic Liver Disease
由: Andrea Pasta, et al.
出版: (2025-01-01)

Liver cancer risk and changes in lifestyle habits after successful hepatitis C virus therapy post-DAA HCV therapy: lifestyle changes and liver cancer risk
由: Núria Granel, et al.
出版: (2025-02-01)

Examining the prevalence of hepatic steatosis and advanced fibrosis using non-invasive measures across Canada: A national estimate using the Canadian Health Measures Survey (CHMS) from 2009-2019
由: Jacob Romano, et al.
出版: (2025-01-01)

Predictors of Significant Fibrosis Among People Living with HIV with Metabolic Dysfunction- Associated Steatotic Liver Disease
由: Thaninee Prasoppokakorn, et al.
出版: (2024-12-01)